• Research and Development

  Esbriet Extends Survival Rates Among People with IPF by 30%

  Posted by Pulmonary Fibrosis News Moderator on December 20, 2018 at 10:44 am

  Esbriet (pirfenidone) can improve survival rates of people with idiopathic pulmonary fibrosis by 30 percent, a real-world analysis shows. Learn more here.

  Are you being/have you been treated with Esbriet? How do you feel about this news?

  replied 6 years, 1 month ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply